Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

17.35USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$17.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,276
52-wk High
$47.67
52-wk Low
$12.75

Latest Key Developments (Source: Significant Developments)

Opiant Prices Public Offering Of 706,000 Common Shares At $17 Per Share
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 706,000 COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

Opiant Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.OPIANT PHARMACEUTICALS- NET PROCEEDS TO BE USED TO ADVANCE ALCOHOL USE DISORDER & BULIMIA NERVOSA CLINICAL PROGRAMS, & FOR GENERAL CORPORATE PURPOSES.  Full Article

Opiant Pharmaceuticals Announces Contract With Biomedical Advanced Research And Development Authority
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES CONTRACT WITH BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY FOR UP TO $4.6 MILLION TO ACCELERATE DEVELOPMENT OF OPNT003, NASAL NALMEFENE, FOR TREATMENT OF OPIOID OVERDOSE.OPIANT PHARMACEUTICALS - EXPECT TO BEGIN PIVOTAL PHARMACOKINETIC STUDY REQUIRED FOR APPROVAL OF OPNT003 BY FDA IN 2019.  Full Article

Opiant Pharma And Consort Medical PLC Announce Manufacturing Agreement
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Consort Medical PLC ::OPIANT PHARMACEUTICALS, INC. AND CONSORT MEDICAL PLC ANNOUNCE MANUFACTURING AGREEMENT FOR OPNT003, INTRANASAL NALMEFENE, FOR TREATMENT OF OPIOID OVERDOSE.OPIANT PHARMACEUTICALS INC - AESICA & BESPAK WILL WORK WITH OPIANT TO PRODUCE A PRE-FILLED DELIVERY NASAL SPRAY WITH NALMEFENE.OPIANT PHARMACEUTICALS INC - AESICA WILL SUPPLY OPIANT WITH CLINICAL SAMPLES AND REGISTRATION BATCHES FOR PURPOSES OF PERFORMING CLINICAL STUDIES.OPIANT PHARMACEUTICALS INC - UPON APPROVAL BY U.S. FDA, AESICA AND BESPAK WILL MANUFACTURE AND SUPPLY COMMERCIAL DEVICE FOR OPIANT.OPIANT PHARMACEUTICALS INC - OPIANT INTENDS TO INITIATE A CONFIRMATORY PHARMACOKINETIC STUDY IN EARLY 2019.OPIANT PHARMACEUTICALS INC - OPIANT INTENDS TO PURSUE A 505(B)(2) DEVELOPMENT PATH FOR OPNT003.OPIANT PHARMACEUTICALS INC - OPIANT ANTICIPATES POTENTIAL TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020.OPIANT PHARMACEUTICALS INC - OPIANT RETAINS FULL COMMERCIAL RIGHTS TO OPNT-003.  Full Article

Consort Medical, Opiant To Develop Delivery Device For Opioid Overdose Treatment
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Consort Medical PLC ::SIGNS DEVELOPMENT AGREEMENTS WITH OPIANT PHARMACEUTICALS.OPIANT WORKING WITH CO TO DEVELOP A DELIVERY DEVICE FOR OPNT003 FOR TREATMENT OF OPIOID OVERDOSE.CO, OPIANT INTEND TO DEVELOP A READY-TO-USE NASAL-DELIVERED VERSION OF NALMEFENE FOR REVERSAL OF OPIOID OVERDOSE.AFTER COMPLETION OF OPNT003 FORMULATION STUDIES, OPIANT INTENDS TO INITIATE CONFIRMATORY PHARMACOKINETIC STUDY IN 2019.BASED ON PREVIOUSLY OBTAINED FEEDBACK FROM FDA, OPIANT INTENDS TO PURSUE A 505(B)(2) DEVELOPMENT PATH FOR OPNT003.ANTICIPATES POTENTIAL TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020.OPIANT RETAINS FULL COMMERCIAL RIGHTS TO OPNT-003.  Full Article

Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE.OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​.OPIANT PHARMACEUTICALS - ROYALTY & MILESTONE PAYMENTS DUE TO SWK HOLDINGS WILL NOW BE REDUCED TO 10%.  Full Article

Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.OPIANT PHARMACEUTICALS INC - QTRLY ‍NET LOSS PER COMMON SHARE $2.77​.  Full Article

Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​.  Full Article

Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​.  Full Article

Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update.Q4 revenue $3.75 million versus $300,000.‍Opiant Pharmaceuticals Inc - appointed David O'Toole as chief financial officer​.Opiant Pharmaceuticals Inc - qtrly loss per share $0.17‍​.  Full Article

UPDATE 1-Consort, Opiant to develop nasal spray for opioid overdose treatment

Sept 10 Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.